Drugs / Pyrifazimine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04670120 | Mar → Jun 2021 | pulmonary tuberculosis | Beijing Chest Hospital | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pyrifazimine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04670120 ↗ |
| Known as | TBI-166 | “The new drug pyrifazimine (previous name: TBI-166) developed by the Institute of Materia Medica of the Chinese Academy of Medical Sciences which is Beijing Union Pharmaceutical...” NCT04670120 ↗ |